Andre Uddin
Stock Analyst at Research Capital
(4.70)
# 737
Out of 4,356 analysts
91
Total ratings
45%
Success rate
30.6%
Average return
Main Sectors:
Stocks Rated by Andre Uddin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSXV: TLT Theralase Technologies Inc. | Maintained: Buy | $0.70 | $0.225 | +211.11% | 7 | May 25, 2026 | |
| TSXV: COV Covalon Technologies Ltd. | Maintained: Buy | $2.90 | $2.17 | +33.64% | 1 | May 22, 2026 | |
| NGEN NervGen Pharma | Maintained: Buy | $5.5 | $2.07 | +165.70% | 4 | Apr 10, 2026 | |
| TSX: EDT Spectral Medical Inc. | Maintained: Buy | $3.50 | $1.42 | +146.48% | 2 | Mar 25, 2026 | |
| TSX: SVA Sernova Biotherapeutics Inc | Maintained: Buy | $3.50 → $0.60 | $0.14 | +328.57% | 3 | Jun 19, 2025 | |
| TSX: MDNA Medicenna Therapeutics Corp. | Maintained: Buy | $2.21 → $3.75 | $0.425 | n/a | 8 | Apr 28, 2025 | |
| TSX: GUD Knight Therapeutics Inc. | Upgraded: Buy | $6.50 → $7.50 | $8.19 | n/a | 11 | Mar 11, 2025 | |
| TSX: MDP Medexus Pharmaceuticals Inc. | Maintained: Buy | $5.50 → $5.90 | $3.88 | n/a | 9 | Mar 26, 2024 | |
| ABILF Ability Inc. | Maintained: Buy | $0.8 | $0.000001 | n/a | 1 | Aug 31, 2023 | |
| VPHIF Valeo Pharma Inc. | Maintained: Buy | $0.87 → $0.72 | $0.000001 | n/a | 4 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25.00 | $0.43 | n/a | 2 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 | $0.000001 | n/a | 1 | Dec 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1.60 → $2.21 | $0.015 | n/a | 3 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4.65 → $1.50 | $16.69 | n/a | 2 | May 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.60 → $2.80 | $1.11 | n/a | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16.20 | $9.53 | n/a | 8 | Apr 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6.16 | $0.000001 | n/a | 9 | Feb 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.57 | n/a | 7 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $15.33 | n/a | 4 | Oct 31, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $10.99 | n/a | 1 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $1.91 | n/a | 1 | May 17, 2017 |
Theralase Technologies Inc.
May 25, 2026
Maintained: Buy
Price Target: $0.70
Current: $0.225
Upside: +211.11%
Covalon Technologies Ltd.
May 22, 2026
Maintained: Buy
Price Target: $2.90
Current: $2.17
Upside: +33.64%
NervGen Pharma
Apr 10, 2026
Maintained: Buy
Price Target: $5.5
Current: $2.07
Upside: +165.70%
Spectral Medical Inc.
Mar 25, 2026
Maintained: Buy
Price Target: $3.50
Current: $1.42
Upside: +146.48%
Sernova Biotherapeutics Inc
Jun 19, 2025
Maintained: Buy
Price Target: $3.50 → $0.60
Current: $0.14
Upside: +328.57%
Medicenna Therapeutics Corp.
Apr 28, 2025
Maintained: Buy
Price Target: $2.21 → $3.75
Current: $0.425
Upside: n/a
Knight Therapeutics Inc.
Mar 11, 2025
Upgraded: Buy
Price Target: $6.50 → $7.50
Current: $8.19
Upside: n/a
Medexus Pharmaceuticals Inc.
Mar 26, 2024
Maintained: Buy
Price Target: $5.50 → $5.90
Current: $3.88
Upside: n/a
Ability Inc.
Aug 31, 2023
Maintained: Buy
Price Target: $0.8
Current: $0.000001
Upside: n/a
Valeo Pharma Inc.
Jun 14, 2023
Maintained: Buy
Price Target: $0.87 → $0.72
Current: $0.000001
Upside: n/a
May 10, 2021
Maintained: Buy
Price Target: $25.00
Current: $0.43
Upside: n/a
Dec 11, 2020
Upgraded: Buy
Price Target: $8
Current: $0.000001
Upside: n/a
Oct 30, 2020
Maintained: Buy
Price Target: $1.60 → $2.21
Current: $0.015
Upside: n/a
May 8, 2020
Maintained: Buy
Price Target: $4.65 → $1.50
Current: $16.69
Upside: n/a
Apr 16, 2020
Maintained: Hold
Price Target: $7.60 → $2.80
Current: $1.11
Upside: n/a
Apr 7, 2020
Downgraded: Hold
Price Target: $16.20
Current: $9.53
Upside: n/a
Feb 26, 2020
Maintained: Buy
Price Target: $6.16
Current: $0.000001
Upside: n/a
Jan 13, 2020
Maintained: Buy
Price Target: n/a
Current: $2.57
Upside: n/a
Oct 31, 2019
Maintained: Buy
Price Target: $10
Current: $15.33
Upside: n/a
Nov 13, 2017
Rated: Buy
Price Target: n/a
Current: $10.99
Upside: n/a
May 17, 2017
Maintained: Buy
Price Target: $15
Current: $1.91
Upside: n/a